Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP-
dc.contributor.authorFAIAO-FLORES, Femanda-
dc.contributor.authorCOELHO, Paulo Rogerio Pinto-
dc.contributor.authorARRUDA-NETO, Joao Dias Toledo-
dc.contributor.authorMARIA-ENGLER, Silvya Stuchi-
dc.contributor.authorMARIA, Durvanei Augusto-
dc.identifier.citationTOXICOLOGY IN VITRO, v.27, n.4, Special Issue, p.1196-1204, 2013-
dc.description.abstractBoron Neutron Capture Therapy (BNCT) involves the selective accumulation of boron carriers in tumor tissue followed by irradiation with a thermal or epithermal neutron beam. This therapy is therefore a cellular irradiation suited to treat tumors that have infiltrated into healthy tissues. BNCT has been used clinically to treat patients with cutaneous melanomas which have a high mortality. Human normal melanocytes and melanoma cells were treated with BNCT at different boronophenylalanine concentrations for signaling pathways analysis. BNCT induced few morphological alterations in normal melanocytes, with a negligible increase in free radical production. Melanoma cells treated with BNCT showed significant extracellular matrix (ECM) changes and a significant cyclin D1 decrease, suggesting cell death by necrosis and apoptosis and cell cycle arrest, respectively. BNCT also induced a significant increase in cleaved caspase-3 and a decrease in the mitochondrial electrical potential with selectivity for melanoma cells. Normal melanocytes had no significant differences due to BNCT treatment, confirming the data from the literature regarding the selectivity of BNCT. The results from this study suggest that some signaling pathways are involved in human melanoma treatment by BNCT, such as cell cycle arrest, ECM changes and intrinsic apoptosis.-
dc.relation.ispartofToxicology in Vitro-
dc.subjectBoron Neutron Capture Therapy (BNCT)-
dc.subjectBoronophenylalanine (BPA)-
dc.subjectNormal melanocytes-
dc.subjectCell cycle arrest-
dc.subject.othercutaneous melanoma-
dc.subject.otherskin melanoma-
dc.titleCell cycle arrest, extracellular matrix changes and intrinsic apoptosis in human melanoma cells are induced by Boron Neutron Capture Therapy-
dc.rights.holderCopyright PERGAMON-ELSEVIER SCIENCE LTD-
dc.type.categoryoriginal article-
dc.type.versionpublishedVersion-, Paulo Rogerio Pinto:Inst Nucl & Energy Res, Sao Paulo, Brazil-, Joao Dias Toledo:Univ Sao Paulo, Inst Phys, Sao Paulo, Brazil; Unitalo Univ Ctr, Sao Paulo, Brazil-, Silvya Stuchi:Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol, Sao Paulo, Brazil-, Durvanei Augusto:Butantan Inst, Biochem & Biophys Lab, Sao Paulo, Brazil-
hcfmusp.description.issueSpecial Issue-
hcfmusp.relation.referenceBaker GL, 2005, CELL CYCLE, V4, P330-
hcfmusp.relation.referenceBarth RF, 2004, INT J RADIAT ONCOL, V58, P267, DOI 10.1016/S0360-3016(03)01613-4-
hcfmusp.relation.referenceBarth RF, 2005, CLIN CANCER RES, V11, P3987, DOI 10.1158/1078-0432.CCR-05-0035-
hcfmusp.relation.referenceChakrabartil A., 2012, NANOTECHNOL LIFE SCI, V16, P403-
hcfmusp.relation.referenceChen M, 2009, MOL CANCER RES, V7, P703, DOI 10.1158/1541-7786.MCR-08-0263-
hcfmusp.relation.referenceChen Y, 2001, CANCER RES, V61, P6437-
hcfmusp.relation.referenceCODERRE JA, 1994, INT J RADIAT ONCOL, V30, P643-
hcfmusp.relation.referenceCoelho PRP, 2002, RESEARCH AND DEVELOPMENT IN NEUTRON CAPTURE THERAPY, P197-
hcfmusp.relation.referenceDebatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558-
hcfmusp.relation.referenceEsposito J, 2008, NUCL INSTRUM METH B, V266, P2587, DOI 10.1016/j.nimb.2008.03.239-
hcfmusp.relation.referenceFADOK VA, 1992, J IMMUNOL, V148, P2207-
hcfmusp.relation.referenceFaiao-Flores F, 2011, APPL RADIAT ISOTOPES, V69, P1748, DOI 10.1016/j.apradiso.2011.05.017-
hcfmusp.relation.referenceFaiao-Flores F, 2011, APPL RADIAT ISOTOPES, V69, P1741, DOI 10.1016/j.apradiso.2011.03.005-
hcfmusp.relation.referenceFaiao-Flores F, 2012, RADIAT ENVIRON BIOPH, V51, P319, DOI 10.1007/s00411-012-0416-y-
hcfmusp.relation.referenceFernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686-
hcfmusp.relation.referenceFujita Y, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-63-
hcfmusp.relation.referenceFuller KM, 2003, CURR OPIN BIOTECH, V14, P35, DOI 10.1016/S0958-1669(02)00008-3-
hcfmusp.relation.referenceGnewuch CT, 2002, CELL MOL LIFE SCI, V59, P959, DOI 10.1007/s00018-002-8483-x-
hcfmusp.relation.referenceGonzalez SJ, 2004, APPL RADIAT ISOTOPES, V61, P1101, DOI 10.1016/j.apradiso.2004.05.060-
hcfmusp.relation.referenceGrossmann J, 2001, CELL GROWTH DIFFER, V12, P147-
hcfmusp.relation.referenceHughes AM, 2011, ORAL ONCOL, V47, P1017, DOI 10.1016/j.oraloncology.2011.07.014-
hcfmusp.relation.referenceJUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772-
hcfmusp.relation.referenceKamida A, 2008, INT J RADIAT BIOL, V84, P191, DOI 10.1080/09553000801902125-
hcfmusp.relation.referenceKennady PK, 2004, CYTOM PART A, V62A, P97, DOI 10.1002/cyto.a.20091-
hcfmusp.relation.referenceKoren R, 2001, ACTA HISTOCHEM, V103, P151, DOI 10.1078/0065-1281-00587-
hcfmusp.relation.referenceLi W, 2006, PATHOLOGY, V38, P287, DOI 10.1080/00313020600817951-
hcfmusp.relation.referenceMakino H, 2000, Kidney Int Suppl, V77, pS67-
hcfmusp.relation.referenceMenendez PR, 2009, APPL RADIAT ISOTOPES, V67, pS50, DOI 10.1016/j.apradiso.2009.03.020-
hcfmusp.relation.referenceMenichetti L, 2009, APPL RADIAT ISOTOPES, V67, pS336, DOI 10.1016/j.apradiso.2009.03.058-
hcfmusp.relation.referenceMishima Y, 1996, CANCER NEUTRON CAPTURE THERAPY, P1-
hcfmusp.relation.referenceMOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4-
hcfmusp.relation.referenceNakamura H., 2011, ORG BIOMOL CHEM, V10, P1374-
hcfmusp.relation.referenceOHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3-
hcfmusp.relation.referenceOkada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412-
hcfmusp.relation.referencePawlik TM, 2003, CRIT REV ONCOL HEMAT, V45, P245, DOI 10.1016/S1040-8428(02)00080-X-
hcfmusp.relation.referencePICKERING JG, 1991, AM J PATHOL, V138, P1225-
hcfmusp.relation.referenceSauter ER, 2002, CANCER RES, V62, P3200-
hcfmusp.relation.referenceSoengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454-
hcfmusp.relation.referenceJoensuu Heikki, 2011, Duodecim, V127, P1697-
hcfmusp.relation.referenceToppino A, 2013, CHEM-EUR J, V19, P720, DOI 10.1002/chem.201201634-
hcfmusp.relation.referencevan Kempen LCLT, 2008, INT J CANCER, V122, P1019, DOI 10.1002/ijc.23147-
hcfmusp.relation.referenceVERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I-
hcfmusp.relation.referenceWallace KB, 2000, ANNU REV PHARMACOL, V40, P353, DOI 10.1146/annurev.pharmtox.40.1.353-
hcfmusp.relation.referenceWunrau C, 2009, ARTHRITIS RHEUM, V60, P2606, DOI 10.1002/art.24782-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/Outros
Outros departamentos - FM/Outros

Artigos e Materiais de Revistas Científicas - ODS/03
ODS/03 - Saúde e bem-estar

Files in This Item:
File Description SizeFormat 
  Restricted Access
publishedVersion (English)1.1 MBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.